Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity

NCT07738276 on ClinicalTrials.gov · last registry update 2026-08-03

A small phase 3 — 60 participants, against a typical 424. Due to report 11 June 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: Change in 6-Minute Walk Distance. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for heart failure — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: NOT_YET_RECRUITING
Phase: P3
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Shahid Beheshti University of Medical Sciences
Sponsor type: Other
Enrollment: 60
Started: 2026-07-18
Primary completion: 2027-06-11 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in 6-Minute Walk Distance

Conditions studied

Heart Failure and Reduced Ejection Fraction · Obesity & Overweight · Tirzepatide

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.